Insulin therapy in the elderly patient with diabetes

American Journal Geriatric Pharmacotherapy

Volumn 9, Issue 1, 2011, Pages 24-36

  Tanwani, Lal K ^a  

^a Diabetes Endocrinology and Metabolism   (United States)

Author keywords

elderly; geriatric; human insulin; insulin analogs; type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; ISOPHANE INSULIN PLUS HUMAN INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG SAFETY; EMBASE; FALL RISK; FRAIL ELDERLY; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PEN; INSULIN TREATMENT; LIFE EXPECTANCY; LONG TERM CARE; MEDLINE; META ANALYSIS (TOPIC); NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME; NURSING HOME PATIENT; PANCREAS ISLET BETA CELL; PATIENT PREFERENCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SELF INJECTION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 79953691433     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.02.006     Document Type: Article

References (91)

1. Centers for Disease Control and Prevention (CDC). National diabetes fact sheet, 2007. General information and national estimates on diabetes in the United States. Atlanta, Ga: US Department of Health and Human Services; 2007.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
3. California Healthcare Foundation. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(Suppl 5):S265-S280.
4. Suh DC, Kim CM, Choi IS, Plauschinat CA. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56:484-492.
5. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the US. Diabetes Care. 2001;24:1936-1940. (Pubitemid 33716504)
6. Sloan FA, Bethel MA, Ruiz D Jr, et al. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med. 2008;168:192-199. (Pubitemid 351185887)
7. Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921-927. (Pubitemid 46762754)
8. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: Special considerations. Drugs Aging. 2001;18:31-44. (Pubitemid 32182131)
9. Resnick B. Diabetes management: The hidden challenge of managing hyperglycemia in long-term care settings. Ann Long-Term Care. 2005;26-32. (Pubitemid 41161165)
10. Pandya N, Nathanson E. Managing diabetes in long-term care facilities: Benefits of switching from human insulin to insulin analogs. J Am Med Directors Assoc. 2010;11:171-178.
11. Sinclair AJ, Girling AJ, Bayer AJ, for the All Wales Research into Elderly (AWARE) Study. Cognitive dysfunction in older subjects with diabetes mellitus: Impact on diabetes self-management and use of care services. Diabetes Res Clin Pract. 2000;50:203-212.
12. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982. (Pubitemid 36121050)
13. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284-289.
14. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;373:1798-1807.
15. Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr. 1998;22:77-81. (Pubitemid 28117569)
16. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
17. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349. (Pubitemid 35215326)
18. American Medical Directors Association. Diabetes management in the long-term care setting: clinical practice guideline. Columbia, Md: American Medical Directors Association (AMDA); 2008.
19. Constans T. Plasma glucose goals and therapeutic management in elderly diabetic patients. Diabetes Metab (Paris). 2005;31(Spec No 2):5S58-5S61.
20. European Diabetes Working Party for Older People. Clinical guidelines for type 2 diabetes mellitus. 2004 http://www.eugms.org/index.php?pid=83. Accessed February 13, 2011.
21. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci. 2001;56:M5-M13. (Pubitemid 32042962)
22. Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA. 2006;295:1935-1940.
23. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
24. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412. (Pubitemid 30609442)
25. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 2003;57:231-239. (Pubitemid 36897689)
26. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511-530. (Pubitemid 38858301)
27. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391-396.
28. Turchin A, Matheny ME, Shubina M, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153-1157.
29. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)
30. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
31. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
32. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351-357.
33. Russell LB, Valiyeva E, Roman SH, et al. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28:1611-1617. (Pubitemid 40923073)
34. Pandya N, Thompson S, Sambamoorthi U. The prevalence and persistence of sliding scale insulin use among newly admitted elderly nursing home residents with diabetes mellitus. J Am Med Directors Assoc. 2008;9:663-669.
35. Feldman SM, Rosen R, DeStasio J. Status of diabetes management in the nursing home setting in 2008: A retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Directors Assoc. 2009;10:354-360.
36. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-591. (Pubitemid 38174086)
37. Moghissi ES, Korytkowski MT, Dinardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-1131.
38. Levetan CS, Magee MF. Hospital management of diabetes. Endocrinol Metab Clin North Am. 2000;29:745-770. (Pubitemid 32016688)
39. Browning LA, Dumo P. Sliding-scale insulin: An antiquated approach to glycemic control in hospitalized patients. Am J Health Syst Pharm. 2004;61:1611-1614. (Pubitemid 39481406)
40. American Association of Clinical Endocrinologists. Management of hyperglycemia in the non ICU setting: Understanding the mechanisms of hyperglycemia for the inpatient with diabetes. http://resources.aace.com/pages. asp?id=25. Accessed February 13, 2011.
41. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012. (Pubitemid 29254858)
42. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71:385-2, 394.
43. Reza M, Taylor CD, Towse K, et al. Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;55:201-207. (Pubitemid 34163291)
44. Sinclair AJ. Special considerations in older adults with diabetes: Meeting the challenge. Diabetes Spectr. 2006;19:229-233. (Pubitemid 44885522)
45. de Wet H, Levitt N, Tipping B. Executive cognitive impairment detected by simple bedside testing is associated with poor glycaemic control in type 2 diabetes. S Afr Med J. 2007;97:1074-1076. (Pubitemid 350285951)
46. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174-183. (Pubitemid 40096614)
47. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
48. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA. 2003;289:2254-2264. (Pubitemid 37430194)
49. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112. (Pubitemid 40616620)
50. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Med Gen Med. 2007;9:12.
51. NovoLog mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]) [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; May 2010.
52. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648-659. (Pubitemid 47261846)
53. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086. (Pubitemid 37339502)
54. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274. (Pubitemid 44125921)
55. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613.
56. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: A review of clinical studies. J Diabetes Complications. 2007;21:196-204.
57. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569-1581. (Pubitemid 44856694)
58. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
59. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416.
60. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987.
61. Ashwell SG, Bradley C, Stephens JW, et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with type 1 diabetes. Diabetes Care. 2008;31:1112-1117.
62. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med. 2001;18:619-625. (Pubitemid 32823058)
63. Preumont V, Buysschaert M, De BS, Mathieu C. Insulin detemir in routine clinical practice: A 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort. Acta Clin Belg. 2009;64:49-55.
64. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55:1735-1740. (Pubitemid 350043780)
65. Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: Open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol. 2008;45:53-59.
66. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study. Diabetes Care. 1998;21:1236-1239. (Pubitemid 28365676)
67. Meece J. When oral agents fail: Optimizing insulin therapy in the older adult. Consultant Pharm. 2009;24(Suppl B):11-17.
68. Haas LB. Optimizing insulin use in type 2 diabetes: Role of basal and prandial insulin in long-term care facilities. J Am Med Directors Assoc. 2007;8:502-510. (Pubitemid 47532934)
69. Danne T, Rave K, Bittner C, et al. Pharmacokinetics and safety of insulin glulisine in children and adolescents with type 1 diabetes [abstract]. Diabetes. 2004;53(Suppl 2):A600.
70. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 1999;55:199-203. (Pubitemid 29244647)
71. Home PD, Lindholm A, Riis A. Insulin aspart vs human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med. 2000;17:762-770. (Pubitemid 32000974)
72. Tamas G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001;54:105-114. (Pubitemid 32964681)
73. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis. Diabetes Obes Metab. 2009;11:53-59.
74. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904-1909. (Pubitemid 28478291)
75. Krones R, Schutte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009;11:41-44.
76. Meneilly GS. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:754-755. (Pubitemid 47261857)
77. Velussi M. Lispro insulin treatment in comparison with regular human insulin in type 2 diabetic patients living in nursing homes. Diabetes Nutr Metab. 2002;15:96-100. (Pubitemid 34546203)
78. Hendra TJ. Diabetes and insulin therapy in older people. Br J Diab Vasc Dis. 2005;5:19-23. (Pubitemid 40352805)
79. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66:31-49. (Pubitemid 43144962)
80. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27:1113-1125. (Pubitemid 41393909)
81. Raskin P, Matfin G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab. 2009;11:27-32.
82. Velojic-Golubovic M, Mikic D, Pesic M, et al. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009;32:23-27.
83. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thricedaily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8:58-66.
84. Oyer DS, Shepherd MD, Coulter FC, et al. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med. 2009;122:1043-1049.
85. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32:1007-1013.
86. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265. (Pubitemid 40170923)
87. Herz M, Sun B, Milicevic Z, et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther. 2002;24:73-86. (Pubitemid 34117525)
88. Jang HC, Lee SR, Vaz JA. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: A subgroup analysis of the PRESENT Korea NovoMix study. Diabetes Obes Metab. 2009;11:20-26.
89. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573. (Pubitemid 40923066)
90. Marcus A. Diabetes care - insulin delivery in a changing world. Medscape J Med. 2008;10:120.
91. Brunton S. Initiating insulin therapy in type 2 diabetes: Benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10:247-256.